Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

CONCLUSION: Clinically-tested patients with breast and ovarian cancer in two large, diverse states had 8% to 15% prevalence of actionable pathogenic variants. Substantial testing gaps and disparities among patients with ovarian cancer are targets for improvement. PMID: 30964716 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30964716?dopt=Abstract

Source: Clinical Breast Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ Tags: J Clin Oncol Source Type: research